{"organizations": [], "uuid": "94bcb4538dbf74e305503c81ef771267095c0ab2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180201.html", "section_title": "Archive News &amp; Video for Thursday, 01 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-roche-holding-ag-drugs-chief-says/brief-roche-holding-ag-drugs-chief-says-immunotherapy-competitors-taking-share-from-avastin-idUSFWN1PR09Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Roche Holding AG Drugs Chief Says Immunotherapy Competitors Taking Share From Avastin", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-01T17:07:00.000+02:00", "replies_count": 0, "uuid": "94bcb4538dbf74e305503c81ef771267095c0ab2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-roche-holding-ag-drugs-chief-says/brief-roche-holding-ag-drugs-chief-says-immunotherapy-competitors-taking-share-from-avastin-idUSFWN1PR09Z", "ord_in_thread": 0, "title": "BRIEF-Roche Holding AG Drugs Chief Says Immunotherapy Competitors Taking Share From Avastin", "locations": [], "entities": {"persons": [{"name": "john miller", "sentiment": "none"}], "locations": [{"name": "u.s", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-roche holding ag", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "roche holding ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - Roche Holding Ag:\n* CFO SAYS EXPECTS HIGH THREE DIGIT MILLION TAX BENEFIT FROM U.S. TAX REFORM\n* CEO SAYS U.S. TAX REFORM HAS BOOSTED U.S. COMPETITIVENESS\n* DRUGS DIVISION CHIEF SAYS OCREVUS HAS 5 PERCENT MULTIPLE SCLEROSIS MARKET SHARE AFTER THREE QUARTERS OF SALES, SEES NO SLOWING IN UNITED STATES\n* CEO EXPECTS OCREVUS TO “EASILY” EXCEED 1 BILLION SFR IN SALES IN 2018\n* DRUGS CHIEF EXPECTS SIMILAR EROSION FOR HERCEPTIN AS RITUXAN AS BIOSIMILARS ENTER MARKET\n* DRUGS CHIEF SAYS IMMUNOTHERAPY COMPETITORS TAKING MARKET SHARE FROM AVASTIN IN U.S. LUNG CANCER TREATMENT, RESULTING IN REVENUE DECLINE Source text for Eikon: Further company coverage: (Reporting by John Miller)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-01T17:07:00.000+02:00", "crawled": "2018-02-02T12:50:02.030+02:00", "highlightTitle": ""}